Observational Longitudinal Study of Magnetic Resonance Imaging, Specimen Biomarkers, and Clinical Progression in Progressive Supranuclear Palsy and Corticobasal Degeneration
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Progressive Supranuclear Palsy
- Sponsor
- University of California, San Francisco
- Enrollment
- 110
- Locations
- 2
- Primary Endpoint
- Progressive Supranuclear Palsy Rating Scale
- Status
- Completed
- Last Updated
- 11 months ago
Overview
Brief Summary
The purpose of this study is to evaluate several different tests, including brain imaging, eye movement testing, body fluid samples, measurements of memory and other thinking abilities, and measures of functional independence in the hope that this information can be used to guide diagnosis and treatment of PSP and CBD in the future. Recent advances in our understanding of the biological causes of these diseases offer hope for new treatments. As such treatments are developed, sensitive and specific biological measurements (biomarkers) will be needed to provide precise and direct measures of the state of the brain, which will improve the statistical power of clinical trials. Brain imaging with Magnetic Resonance Imaging (MRI) has previously been used to measure disease-related changes in the brain. The goal of this study is to identify the best methods of analysis (including eye movements, imaging, and behavioral measures) for tracking PSP and CBD over time. In addition, certain biomarkers in the blood and cerebrospinal fluid might also be useful for following these diseases over time. This study will examine the value of blood and CSF biomarkers relative to brain imaging and functional measures.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Clinical diagnosis of Progressive Supranuclear Palsy or Corticobasal Degeneration
- •Must have a reliable study partner who has frequent contact with the subject
- •Willing and able to undergo testing procedures
Exclusion Criteria
- •Significant neurological disease other than PSP or CBD
- •Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body
Outcomes
Primary Outcomes
Progressive Supranuclear Palsy Rating Scale
Time Frame: Baseline, 6 months and 1 year
Change from baseline
Secondary Outcomes
- Brain volume on MRI(Baseline, 6 months and 1 year)
- Eye movement function(Baseline, 6 months and 1 year)